Amanda Morgan, MD
Pulmonary Disease · Reno, NVNPI 1275743122
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Regeneron Healthcare Solutions, Inc. accounts for 67.0% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $11,357, more than ten times the $299 reported in 2019. Among pulmonary disease clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $186.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$13K
- Sanofi$5K
- GSK$800
- AstraZeneca$379
- Boehringer Ingelheim$194
- Genentech USA, Inc.$97
- plus $422 from 9 others
What the payments were for
- Consulting fees$8,96345%
- Speaking & faculty fees$8,06841%
- Food & beverage$2,67213%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 19 | $13,262 |
| Sanofi | 3 | $4,639 |
| GSK | 53 | $800 |
| AstraZeneca | 14 | $379 |
| Boehringer Ingelheim | 5 | $194 |
| Genentech USA, Inc. | 1 | $97 |
| Intuitive Surgical | 1 | $78 |
| Novartis | 1 | $73 |
| Advanced Respiratory, Inc | 1 | $66 |
| Actelion Pharmaceuticals US, Inc. | 1 | $55 |
| Baxter Healthcare | 2 | $51 |
| Insmed, Inc. | 2 | $41 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| United Therapeutics Corporation | 1 | $19 |
| Genentech, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,793 in reported general payments places this provider in the 90th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 323 | $411,263 |
| OfevNintedanib Esylate | 14 | $205,570 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 99 | $79,237 |
| Spiriva RespimatTiotropium Bromide | 69 | $76,636 |
| NucalaMepolizumab | 20 | $74,757 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $59,542 |
| Dupixent SyringeDupilumab | 16 | $58,161 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 68 | $55,070 |
| Breo ElliptaFluticasone/Vilanterol | 83 | $53,928 |
| HyqviaIgg/Hyaluronidase,recombinant | 21 | $46,124 |
| Wixela InhubFluticasone Propion/Salmeterol | 125 | $35,729 |
| Advair HfaFluticasone Propion/Salmeterol | 44 | $33,665 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 80 | $25,992 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $25,347 |
| Pirfenidone | 30 | $22,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $800 | $627,294536 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $194 | $362,623172 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $379 | $72,982105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Reno
- Charles StahlmannReno$263K
- William GrahamReno$21K
- Steve MashourReno$12K
- Julia ChristopherReno$8K
- Christina SzotReno$7K
- Aleem SuraniReno$2K
- Hafiz MahboobReno$2K
- Kunwardeep DhillonReno$2K
- Aaron VirayReno$2K
- Shibu SkariaReno$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.